NCT01865552View on ClinicalTrials.gov

Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB4 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Healthy
Interventions
BIOLOGICAL

SB4

SC administration

BIOLOGICAL

EU sourced Enbrel

SC administration

BIOLOGICAL

US sourced Enbrel

SC administration

Trial Locations (1)

Unknown

Parexel International GmbH, Berlin

All Listed Sponsors
lead

Samsung Bioepis Co., Ltd.

INDUSTRY

NCT01865552 - Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB4 in Healthy Male Subjects | Biotech Hunter | Biotech Hunter